Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

NCT04094766 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Production plan adjustment

Conditions

Refractory B Acute Lymphoblastic Leukemia
Relapse B Acute Lymphoblastic Leukemia

Interventions

DRUG: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

Sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Collaborators

[object Object]